文献速递造血干细胞移植与细胞治疗

干细胞移植中的初始T细胞去除

Naive T-cell depletion in stem cell transplantation.
PubMed 文献 · Blood Adv · 2020-01-01

异基因造血干细胞移植中,供者T细胞既促进植入与抗肿瘤,又引起移植物抗宿主病。小鼠模型显示初始T细胞导致严重GVHD而记忆T细胞不引起或仅轻度GVHD且保留抗肿瘤功能。基于此的临床试验评估初始T细胞去除的外周血干细胞移植物,在HLA相合移植中显示慢性GVHD和严重急性GVHD发生率极低,机会性感染少于完全T细胞去除移植,复发率无明显增加。随机试验正在进行。

要点

  • 初始T细胞去除可显著降低HLA相合移植后慢性和严重急性GVHD发生率
  • 初始T细胞去除后机会性感染低于完全T细胞去除,复发率无明显增加
  • 随机试验正比较标准未选择移植与初始T细胞去除移植及其他GVHD减少策略

核心结论

  • 初始T细胞去除的外周血干细胞移植在HLA相合移植中显示极低慢性GVHD和严重急性GVHD发生率,机会性感染低于完全T细胞去除且复发率无明显增加。

研究设计与样本

  • 基于小鼠造血干细胞移植模型的实验发现,正在开展评估初始T细胞去除外周血干细胞移植物的临床试验,随机临床试验正在进行中。

主要发现

  • 小鼠模型显示初始T细胞一致引起严重GVHD,而记忆T细胞引起轻度或无GVHD并具有关键移植物抗肿瘤功能。
  • 临床试验显示初始T细胞去除移植后慢性GVHD和严重急性GVHD发生率极低,机会性感染频率低于完全T细胞去除移植,复发率无明显增加。

临床怎么用

  • 初始T细胞去除策略可用于HLA相合移植以减少GVHD并保留抗肿瘤功能,同时探索用于供者淋巴细胞输注和单倍体移植。
  • 相关实验室研究将阐明初始T细胞去除移植中抗肿瘤功能的保留机制,并指导高危复发患者增强移植物抗白血病策略。

局限性

  • 原文未明确报告随机临床试验结果,目前证据主要来自正在进行的临床试验和小鼠模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but can also cause graft-versus-host disease (GVHD), with significant morbidity and mortality. Complete T-cell depletion can not only substantially reduce GVHD rates but can also delay immune reconstitution and increase rates of opportunistic infections and relapse. Murine models have shown that naive T cells (TNs) consistently cause severe GVHD, whereas memory T cells cause milder or no GVHD and have critical graft-versus-tumor function. Informed by experiments performed in murine models of HCT, clinical trials are being conducted to evaluate TN-depleted peripheral blood stem cell (PBSC) grafts. These trials are showing very low rates of chronic GVHD and of serious acute GVHD in the HLA-matched HCT setting, with lower frequencies of opportunistic infections than after fully T-cell-depleted HCT and no apparent increase in relapse rates. Randomized clinical trials are ongoing, comparing standard unselected HCT with TN-depleted PBSCs and other promising GVHD-reduction strategies. Correlative laboratory studies will clarify how antitumor function is retained in TN-depleted HCT and inform strategies to further augment graft-versus-leukemia in patients at a high risk of relapse. TN depletion of donor lymphocyte infusions and of haploidentical stem cell grafts is also being investigated.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bleakley M. Naive T-cell depletion in stem cell transplantation. Blood Adv. 2020. PMID: 33049057. doi:10.1182/bloodadvances.2020001888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。